Zendal Pharmaceutical Group Expanding Vaccine Manufacturing Capacity in Portugal, Including Production of COVID-19 Antigen

Zendal Pharmaceutical Group to Expand Vaccine Manufacturing Capacity in Portugal

The Zendal pharmaceutical group has announced plans to expand its current vaccine manufacturing capacity this year. The group will establish a dedicated center in the north of Portugal solely for the production of serums for human health. The Portuguese Medicines Agency is expected to grant the necessary licenses for operation in the summer.

Initially, the new facility will focus on manufacturing for third parties. One of the key contracts secured by Zendal is with Novavax, to produce the antigen for the American vaccine against the coronavirus. This partnership highlights the company’s commitment to combating the ongoing pandemic. Additionally, Zendal aims to manufacture a serum against pulmonary tuberculosis, which is currently in the final phase of a clinical trial.

During the recent shareholders meeting, Zendal announced its financial performance for the previous year. The group closed 2022 with a turnover of 120.1 million euros, reflecting its strong position in the pharmaceutical industry. Furthermore, 2022 marked a year of management reorganization for Zendal, with the establishment of the general management position and Global Operations Management.

The expansion of Zendal’s vaccine manufacturing capacity demonstrates the company’s dedication to meeting the growing demand for vaccines and contributing to global health initiatives. With the establishment of the new center in Portugal, Zendal is poised to play a significant role in the production of life-saving serums.

What impact did Zendal’s reorganization of management have on the company’s strong financial performance in 2022

Zendal Pharmaceutical Group is set to expand its vaccine manufacturing capacity in Portugal this year. The company plans to establish a dedicated center in northern Portugal for the production of serums for human health. The Portuguese Medicines Agency is expected to grant the necessary licenses for operation in the summer.

Initially, the new facility will focus on manufacturing for third parties. Zendal has already secured a key contract with Novavax to produce the antigen for its COVID-19 vaccine. This partnership highlights Zendal’s commitment to combating the ongoing pandemic. Additionally, the company aims to manufacture a serum against pulmonary tuberculosis, which is currently in the final phase of a clinical trial.

At a recent shareholders meeting, Zendal reported a strong financial performance for the previous year, closing 2022 with a turnover of 120.1 million euros. This demonstrates the company’s strong position in the pharmaceutical industry. In addition, 2022 saw a reorganization of management at Zendal, with the establishment of the general management and Global Operations Management positions.

The expansion of Zendal’s vaccine manufacturing capacity reflects the company’s dedication to meeting the increasing demand for vaccines and contributing to global health initiatives. By establishing a new center in Portugal, Zendal is poised to play a significant role in the production of life-saving serums.